Expansion of Biomedical Bonding AB:s Board of Directors

Report this content

With the growing need for novel treatments in the orthopedic and dental market, Biomedical Bonding AB (BMB) is continuing to pursue an expansion of its organization. BMB is now proud to announce that Lena Söderström and Catrin Molund has joined as members of the board.

Biomedical Bonding AB aims to introduce a new paradigm in bone fracture and restoration surgery via our composite resin technology Bonevolent™. With customizable implant treatments focused on tissue-friendliness and safety, we want to improve the surgical outcome and enhance the patient life quality. Its simplicity provides surgeons with earlier unmet freedom-to-operate to master each individual fracture independent of complexity.

Founder and CEO, Prof. Michael Malkoch further explains:
BMB’s technology is unique with the vision to fulfill the current unmet need that is articulated by orthopedic surgeons and dentists. As the company is progressing with its Bonevolent™ platform, it is evident that our organization needs to be strengthen. I am excited to have Lena and Catrin joining BMB as Board Members as they have complementary and broad experiences suited for our innovative medtech company.

The appointment will help BMB move toward its vision of introducing a new Standard-of-Care (SoC) in fracture and bone restoration surgery on the Global market.

More about Lena and Catrin can be found bellow:
Lena Stöderström has a Bachelor of Medical Science and an Executive MBA from Uppsala University. Lena has thirty years of experience in management positions from international pharmaceutical companies and the medical device industry. Her broad range of experience includes positions with people and project management, business development, international marketing and manufacturing. She has been the CEO of Senzime, Isconova and Kibion and she is member of the board of Uppsala university Invest AB, Dicot AB, Agricam AB and Stockholm Chamber of Commerce. Lena is also the chairman of the board for SLU Holding and Inficure Bio AB. 

Catrin Molund has a degree from Uppsala University and over 20 years of experience in the pharmaceutical and medical device industry from companies such as Senzime, Orexo, Phadia, Amersham Biosciences and Pyrosequencing. Positions include roles as VP Global Marketing & Business Development, IT Director, International Marketing and Project Management. She has a track record of heading marketing strategies, global product launches and international sales. Her experience also covers design and implementation of licensing and distribution agreements as well as business development strategies. Catrin currently holds a VP Global Marketing & Business Development position at Senzime AB and serves at the Board of Directors of Senzime Inc.

For more information, please contact:
Michael Malkoch, Founder and CEO
Phone: +46 (0) 8 121 56 755
E-mail: michael.malkoch@biomedicalbonding.com
Homepage: www.biomedicalbonding.com

Biomedical Bonding AB is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.